ReviewClinical rheumatology2026
Baseline comorbidity assessment may authorize early steroid-sparing therapy in older patients with polymyalgia rheumatica.
Review in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucocorticoids remain the cornerstone of polymyalgia rheumatica (PMR) management, but prolonged use carries significant toxicity risks in older adults. Despite high multi-morbidity prevalence, systematic screening using validated geriatric scales is rarely performed. We evaluated whether baseline systemic comorbidity burden, quantified via the Cumulative Illness Rating Scale for Geriatrics (CIRS-G), is associated with persistent glucocorticoid utilization at 12 months. In this perspective report of 154 older outpatients (mean age 71.74 years) with isolated PMR, baseline comorbidity density maintained a significant exploratory association with 12-month persistent glucocorticoid requirements (adjusted OR 1.11, 95% CI 1.05-1.16; P < 0.001), while the isolated severity score lost significance. Partitioning the cohort into true empirical population tertiles revealed that persistent therapy requirements rose from 1.96% (scores ≤ 21) to 44.23% (scores > 25, P < 0.001). A scales-based comorbidity assessment offers a practical operationalization of the 2024 EULAR/ACR Treat-to-Target recommendations, optimizing baseline risk stratification during weaning.
Indexed as
Identifiers
42720710What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.